IBT
GILD icon

International Biotechnology Trust’s Gilead Sciences GILD Stock Holding History

International Biotechnology Trust’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$17.5M Buy
233,584
+89,000
+62% +$6.85M 5.9% 3
2023
Q2 		$11.1M Buy
144,584
+87,000
+151% +$6.94M 3.39% 11
2023
Q1 		$4.78M Hold
57,584
– – 1.33% 27
2022
Q4 		$4.94M Sell
57,584
-151,200
-72% -$12M 1.53% 22
2022
Q3 		$12.9M Buy
208,784
+199,772
+2,217% +$12.6M 4.13% 5
2022
Q2 		$146K Sell
9,012
-79,772
-90% -$4.94M 1.52% 21
2022
Q1 		$1.08M Sell
88,784
-194,000
-69% -$12.4M 0.24% 55
2021
Q4 		$20.5M Sell
282,784
-120,000
-30% -$8.27M 4.57% 5
2021
Q3 		$28.1M Hold
402,784
– – 6.78% 1
2021
Q2 		$27.7M Buy
402,784
+15,000
+4% +$1M 7.32% 1
2021
Q1 		$25.1M Buy
387,784
+39,500
+11% +$2.55M 6.63% 2
2020
Q4 		$20.3M Buy
348,284
+27,000
+8% +$1.63M 5.54% 6
2020
Q3 		$20.3M Buy
321,284
+18,000
+6% +$1.25M 6.55% 3
2020
Q2 		$22.6M Buy
303,284
+66,000
+28% +$5.06M 7.52% 3
2020
Q1 		$17.7M Sell
237,284
-56,000
-19% -$3.87M 8.08% 2
2019
Q4 		$19.1M Sell
293,284
-23,000
-7% -$1.5M 6.86% 2
2019
Q3 		$20M Hold
316,284
– – 9.26% 1
2019
Q2 		$21.4M Buy
316,284
+38,000
+14% +$2.5M 7.92% 1
2019
Q1 		$18.1M Buy
278,284
+65,000
+30% +$4.32M 6.68% 2
2018
Q4 		$10.5M Buy
213,284
+123,000
+136% +$8.6M 6.5% 4
2018
Q3 		$5.35M Hold
90,284
– – 2.54% 16
2018
Q2 		$6.4M Sell
90,284
-41,000
-31% -$2.9M 2.46% 17
2018
Q1 		$9.9M Buy
131,284
+8,500
+7% +$676K 3.86% 9
2017
Q4 		$8.8M Hold
122,784
– – 3.1% 9
2017
Q3 		$9.95M Buy
122,784
+1,000
+0.8% +$76.5K 3.87% 7
2017
Q2 		$8.62M Buy
121,784
+20,000
+20% +$1.33M 3.28% 9
2017
Q1 		$6.91M Sell
101,784
-74,000
-42% -$5.2M 2.65% 11
2016
Q4 		$12.6M Buy
+175,784
New +$13.1M 5.67% 6

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

International Biotechnology Trust's GILD Position: Q3 2023 in Review

International Biotechnology Trust increased its Gilead Sciences (GILD) stake by 62% in Q3 2023, buying an estimated $6.85M and bringing the position to 233,584 shares worth $17.5M. The position accounts for 5.9% of the portfolio, ranked #3.

International Biotechnology Trust first reported a position in GILD in Q4 2016 and has held it in 28 quarters since. The position peaked at $28.1M in Q3 2021. 1,682 funds tracked by Wall St. Rank hold GILD as of Q3 2023.

  • International Biotechnology Trust held 233,584 shares of Gilead Sciences worth $17.5M as of Q3 2023.
  • International Biotechnology Trust bought 89,000 Gilead Sciences shares in Q3 2023, an estimated $6.85M.
  • Gilead Sciences made up 5.9% of International Biotechnology Trust's portfolio in Q3 2023, its #3 holding.
  • International Biotechnology Trust first reported a position in Gilead Sciences in Q4 2016 and has held it in 28 quarters since.
  • International Biotechnology Trust's Gilead Sciences position peaked at $28.1M in Q3 2021.
  • 1,682 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.